Position Statements

IPOPI statements

IPOPI represents the interests of PID patients internationally with regards to regulatory, legislative and other public policy issues. IPOPI works in cooperation with international institutions, regulatory agencies, politicians and other stakeholder organizations. IPOPI monitors key policy developments and define and develop positions on issues of interest to the PID community in the aim to enhance the legislative, regulatory and public policy environment. Below are the most recent positions statements developed by IPOPI:

IPOPI Statement: Access to IG for patients living with a Primary Immunodeficiency  (8 May 2012)

EU reflection on Chronic Diseases - IPOPI's Statement (5 April 2012)

EUnetHTA JA Public Consultation response (PDF) (5 August 2010)

A response to the EU Commission's public consultation on Rare Diseases – Europe's Challenge (PDF) (July 2010)

Corporate Relations (PDF)

Stakeholder Statements

The following statements are from stakeholder organisations or platforms with which IPOPI collaborates on issues of common interest:

PLUS Position Statement EC Clinical Trials Directive Consultation May 2011 (PDF)
PLUS Dublin Consensus Statement 2010 (PDF)